Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Non Operating Income (2016 - 2025)

Plus Therapeutics has reported Non Operating Income over the past 15 years, most recently at $29000.0 for Q4 2025.

  • Quarterly Non Operating Income rose 1066.67% to $29000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.1 million through Dec 2025, down 512.81% year-over-year, with the annual reading at -$7.1 million for FY2025, 512.81% down from the prior year.
  • Non Operating Income was $29000.0 for Q4 2025 at Plus Therapeutics, down from $59000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $6.7 million in Q2 2025 and troughed at -$13.9 million in Q1 2025.
  • The 5-year median for Non Operating Income is -$3000.0 (2024), against an average of -$348421.1.
  • Year-over-year, Non Operating Income skyrocketed 9362.5% in 2024 and then tumbled 36586.84% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$225000.0 in 2021, then soared by 61.78% to -$86000.0 in 2022, then soared by 155.81% to $48000.0 in 2023, then crashed by 106.25% to -$3000.0 in 2024, then surged by 1066.67% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Non Operating Income are $29000.0 (Q4 2025), $59000.0 (Q3 2025), and $6.7 million (Q2 2025).